-
Mashup Score: 5Behind the Scenes: Patient Education and Decision-Making for CAR T - 13 hour(s) ago
Panelists discuss how health care providers engage in vital conversations with patients about CAR T therapy, focusing on comprehensive education, emotional support, and clear communication about the treatment journey ahead.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1Connecting With Congress to Advance Kidney Cancer Research - 1 day(s) ago
Kidney cancer advocacy efforts have spread the urgency and importance of funding research in the field to members of Congress.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Kidney cancer advocacy efforts have spread the urgency and importance of funding research in the field to members of Congress. #kicsm | @kidneycan @LisaHenske https://t.co/B0Q21dNG4Z
-
-
Mashup Score: 0
The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
.@US_FDA approves encorafenib/cetuximab plus mFOLFOX6 for patients with advanced BRAF V600E+ colorectal cancer. @FDAOncology https://t.co/Luz0UJS99P https://t.co/zIqh9Txvy7
-
-
Mashup Score: 0
Results from a phase 1a trial showed that NX-5948 yielded an overall response rate of 77.8% in later lines of treatment for patients with WM.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
NX-5948 has been granted fast track designation by the FDA for the treatment of adult patients with relapsed or refractory Waldenström macroglobulinemia who have undergone 2 previous lines of therapy including a BTK inhibitor. #hematology | @US_FDA https://t.co/qC5GUFaFuT
-
-
Mashup Score: 03 Things You Should Know About Immunotherapy in DLBCL - 1 day(s) ago
Here are 3 things you should know about immunotherapy in diffuse large B-cell lymphoma.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Cytotoxic T cells play a vital role in the body’s immune defense against tumors. #lymsm | @lymphomaphilia https://t.co/eLOebVv20e
-
-
Mashup Score: 5Optimizing Transition of Care in Multiple Myeloma: Bridging the Gap Between Academic and Community Settings - 2 day(s) ago
A panel of experts on multiple myeloma share clinical practices and discuss the transition of care between academic and community oncology settings.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
A panel of experts on multiple myeloma share clinical practices and discuss the transition of care between academic and community oncology settings. #mmsm | @DoctorAKrishnan @szusmani https://t.co/bepeqTFWoz https://t.co/g5zNNmZwdI
-
-
Mashup Score: 2
Nab-paclitaxel elicited a pathologic complete response rate of 66.3% compared with 57.6% with docetaxel plus carboplatin, the phase 3 HELEN-006 trial found.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Further, 66.3% (95% CI, 61.2%-71.4%) of patients in the nab-paclitaxel group experienced a pCR, vs 57.6% (95% CI, 52.3%-62.9%) of patients in the docetaxel plus carboplatin group (combined odds ratio, 1.54; 95% CI, 1.10-2.14). #bcsm https://t.co/elbnCedTk0
-
-
Mashup Score: 0
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity. #lymsm #ASH24 | @ASH_hematology https://t.co/YzcvgAdlbw
-
-
Mashup Score: 0
Multiple targeted therapies/sequencing possibilities are available following elacestrant’s approval for patients with breast cancer, Maxwell Lloyd, MD, said.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Multiple targeted therapies/sequencing possibilities are available following elacestrant’s approval for patients with breast cancer, Maxwell Lloyd, MD, said. #bcsm #SABCS24 | @SABCSSanAntonio @maxwellRlloyd https://t.co/KBpriJ7890
-
-
Mashup Score: 13
SABCS 2024 saw a variety of potentially practice-changing findings on novel antibody drug conjugates, biomarker data, and surgical interventions.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
CancerNetwork covered the latest data from #SABCS24. Here are the top 10 articles covering potentially practice-changing findings. @MOliveira_MD @judygarber5 @dradityabardia @matteolambe @BCJoyceO @KariWisinski_MD @DrShelleyHwang @Icro_Meattini https://t.co/H0qtgKsfnG
-
Panelists discuss how health care providers engage in vital conversations with patients about CAR T therapy, focusing on comprehensive education, emotional support, and clear communication about the treatment journey ahead. #mmsm | @bhemato https://t.co/E0Pdi9HVyY